Please click on the relevant link for the information you require
All content is applicable to NHS South West London and SWL Providers (including Acute Trusts, Mental Health Trust and Community Services providers).
Melatonin prescribing guidance (New March 2025)
The melatonin prescribing guidance for children and young adults replaces the ‘melatonin – sleep disorders in children and adolescents’ shared care agreement. However, children and adolescents who have been treated in accordance with the previous shared care i.e. melatonin modified release tablets (Circadin), will continue with their treatment. At their next review with the specialist, the treatment will be reviewed and changed, where clinically appropriate to an approved licensed formulation in line with SWL formulary
Safe use of Valproate Policy (New March 2025)
The safe use of valproate policy provides advice and guidance for healthcare professionals to ensure the safe prescribing and dispensing of valproate for all patients across SWL. The policy must be used in conjunction with local standard operating procedures, organisational policies and the Medicines and Healthcare products Regulatory Agency (MHRA) Healthcare Professional Guide.‘Valproate’ is used to mean oral sodium valproate, valproic acid and valproate semi sodium.
Chronic Kidney Disease (CKD)
- Investigation and management of CKD is adults in primary care (updated)
- Sodium glucose co-transporter-2 inhibitors (SGLT2i) for treating CKD (updated)
- Finerenone for treating CKD (New)
COPD guidance (Updated November 2024)
Updated guidance on the management of chronic obstructive pulmonary disease (COPD), including a visual summary.
Dermatology Guidelines (New)
Management of:
- Acne (from age 12 years)
- Atopic Dermatitis
- Atopic Eczema (adults and children),
- Chronic Urticaria
- Hyperhidrosis,
- Psoriasis,
- Wart
